Explore the thriving Anti-Cancer mAbS market with rapid growth from $69.33B in 2024 to $109.88B by 2029 (CAGR 9.3%). Key drivers include rising cance Tuesday, 02 January 2024 12:17 GMT ...

Baystreet.ca News Commentary – The rising burden of cancer is poised to strain both healthcare systems and patient finances, ...

RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and ...

Y-mAbs announces positive Phase 1 Trial 1001 results for GD2-SADA in cancer, plans further studies with optimized radiohapten "Proteus." Quiver AI Summary ...

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products.

Melanie Mills is shaving her head this July to raise £1,000 for MABS Cancer Support Foundation, which is helping her family ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hetronifly (serplulimab) to treat adults ...

Explore the thriving Anti-Cancer mAbS market with rapid growth from $69.33B in 2024 to $109.88B by 2029 (CAGR 9.3%). Key drivers include rising cancer rates and innovations in drug delivery and AI.

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C.

Explore the thriving Anti-Cancer mAbS market with rapid growth from $69.33B in 2024 to $109.88B by 2029 (CAGR 9.3%). Key drivers include rising cancer rates and innovations in drug delivery and AI.